US equities |
NVDA $237.32 ▲+1.44% MU $1,059.39 ▼-1.44% SPCX $164.61 ▲+3.55% TSLA $376.26 ▲+1.53% MSFT $527.87 ▲+2.00% INTC $116.50 ▼-2.37% SNDK $1,714.77 ▼-0.30% AMD $629.43 ▼-0.71%
FinancialContent

Virpax Pharmaceuticals, Inc. - Common Stock (NQ:VRPX)

0.6695 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Virpax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
News headline image
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Reports on Progress of Envelta™
From Virpax Pharmaceuticals
Via Business Wire
News headline image
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
From Virpax Pharmaceuticals
Via Business Wire
News headline image
Virpax Pharmaceuticals 2022 R&D Expenses Grow 122% To $10.8M, Here Are The Details ↗
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) released its financial results for the twelve months ended December 31, 2022, and other recent developments. FY 2022 Financial Highlights 
Via Benzinga
News headline image
Virpax Pharmaceuticals Reports 2022 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Virpax Completes FDA Required Preclinical Toxicology Studies For Its Licensed Molecular Envelope Technology ↗
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX), has completed FDA required preclinical toxicology studies for its licensed Molecular Envelope Technology (MET). MET enhances the delivery of Virpax’s... 
Via Benzinga
News headline image
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)
From Virpax Pharmaceuticals
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Engages Physicians Experienced In Childhood Epilepsy To Assist In Development Of NobrXiol ↗
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) has engaged two physicians experienced in childhood epilepsy, Dr. Kenneth W. Sommerville and Dr. Lawrence Fried, to support the overall development plan for... 
Via Benzinga
News headline image
Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 75 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Virpax Receives pre-IND Application Guidance From The FDA For Its CBD-Based Drug Candidate For Epilepsy ↗
Virpax Pharmaceuticals, Inc. 
Via Benzinga
News headline image
Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  OnThursday, 137 stocks made new 52-week lows. 
Via Benzinga
News headline image
Virpax Pharmaceuticals Reports 2022 Third Quarter Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 456 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  Monday saw 825 companies set new 52-week lows. 
Via Benzinga
News headline image
Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pursues OTC Medical Device Pathway for AnQlar™
From Virpax Pharmaceuticals
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >